Description

Neurocrine Biosciences: CRENESSITY Launch Momentum and Phase III Readouts Create a Powerful Growth Setup!

Neurocrine Biosciences reported first-quarter 2026 results showcasing significant progress in both its commercial portfolio and clinical pipeline. The company achieved over $800 million in net product sales for the first time, representing a 44% year-over-year increase. This growth was primarily driven by INGREZZA, which recorded $657 million in sales, a 20% rise compared to the prior year, fueled by robust volume growth and record new patient additions. CRENESSITY also demonstrated strong traction with $153 million in Q1 sales, supported by steady new patient enrollment, high persistency, and favorable reimbursement. The company reaffirmed its 2026 guidance for INGREZZA sales of $2.7 billion to $2.8 billion and noted CRENESSITY is annualizing at over $600 million, positioning it toward blockbuster status. The acquisition of Soleno Therapeutics and the addition of VYKAT XR to Neurocrine’s commercial portfolio were highlighted, although detailed commentary was limited due to the ongoing tender offer.